AOD-9604 vs Ipamorelin
Research Verdict
Ipamorelin is the stronger research reference for the stated comparison criteria. Ipamorelin: Phase 2 data from Helsinn for post-operative ileus, with selective GH secretagogue effects.
Quick Answers
Which is better, AOD-9604 or Ipamorelin?
Ipamorelin is the stronger research reference for the stated comparison criteria. Ipamorelin: Phase 2 data from Helsinn for post-operative ileus, with selective GH secretagogue effects.
What is the key difference between AOD-9604 and Ipamorelin?
Ipamorelin is a ghrelin receptor agonist causing pulsatile GH release; AOD-9604 is a modified GH fragment with no GH-releasing activity - stimulating GH production vs. using a GH-derived fragment for direct lipolytic effects.
Evidence Comparison
Ipamorelin: Phase 2 data from Helsinn for post-operative ileus, with selective GH secretagogue effects. AOD-9604: Phase 3 failure for obesity. Neither is approved for its studied indication, but ipamorelin has positive Phase 2 efficacy for a defined endpoint.
Evidence Context Favoring AOD-9604
GH fragment lipolysis research, acknowledging Phase 3 efficacy failure.
Evidence Context Favoring Ipamorelin
Research requiring selective GH secretagogue effects without cortisol or prolactin elevation.
Side-by-Side Snapshot
| Evidence grade | AOD-9604: Level D Ipamorelin: Level B |
|---|---|
| Research status | AOD-9604: Preclinical Ipamorelin: Phase 2 |
| Primary category | AOD-9604: Weight Loss & Metabolic Ipamorelin: Growth Hormone |
| Cited studies | AOD-9604: 2 Ipamorelin: 3 |